# US 2024/0189296 A1 · Tryptamine compositions for enhancing neurite outgrowth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189296 A1
- Document ID: US20240189296A1
- Status: Published application
- Kind: A1
- Application number: 18/437,692
- Filed: 2024-02-09
- Published: 2024-06-13
- Earliest claimed: 2016-07-23
- Assignees: Turtle Bear Holdings, LLC
- Applicants: Turtle Bear Holdings, LLC
- Inventors: Paul Edward STAMETS
- Web page: https://patentgrep.com/patent/US20240189296A1

## CPC

- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 36/07: Basidiomycota, e.g. Cryptococcus
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2236/00: Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.

## Claims

### Claim 1

A method for administering psilocybin or psilocin to a subject in need thereof, the method comprising:
a first pharmaceutical dosage form comprising 10 mg to 30 mg of psilocybin, psilocin, pharmaceutically acceptable salts thereof, or a combination thereof; and
a second pharmaceutical dosage form comprising 0.01 mg to 10 mg of psilocybin, psilocin, pharmaceutically acceptable salts thereof, or a combination thereof, 1 to 6 times a day at regular intervals until the until the subject in need thereof does not require administration.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first pharmaceutical dosage form comprises 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 ma, 16 mg, 17 mg, 18 ma, 19 ma, 20 ma, 21 ma, 22 ma, 23 ma, 24 ma, 25 ma, 26 ma, 27 ma, 28 ma, 29 ma, or 30 ma of psilocybin, psilocin, or pharmaceutically acceptable salts thereof; and
the second pharmaceutical dosage form comprises 0.01 mg, 0.02 mg, 0.03 mg, 0.04 mg, 0.05 mg, 0.06 mg, 0.07 mg, 0.08 mg, 0.09 mg, 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5, mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg of psilocybin psilocin, or pharmaceutically acceptable salts thereof.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the first or second pharmaceutical dosage form comprises psilocybin or psilocin containing mushrooms or extracts thereof in an amount to provide an equivalent dose of psilocybin or psilocin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first or second pharmaceutical dosage form further comprises: 10 μg to 200 mg of niacin; one or more pharmaceutically acceptable excipients; or a combination thereof.

### Claim at position 6

6-7. (canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the second pharmaceutical dosage form is administered 1 month, 2 months, 3 months, 4, months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months, 1 year, 2 years, 3 years, 4 years, 5 years, or a decade.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject in need thereof is experiencing mood disorders, depression, anxiety, major depressive disorder, treatment resistant depression, persistent depression, manic depression or bipolar disorder, depressive psychosis, perinatal depression, premenstrual dysphoric disorder, seasonal depression, situational depression, panic disorder, post-traumatic stress disorder, obsessive compulsive disorder, substance abuse disorders, attention deficit/hyperactivity disorder, sleep disorders, eating disorders, schizophrenia, personality disorders, neuronal injuries or physical neurodegeneration, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, frontotemporal dementia, Huntington's disease, adrenal leukodystrophy, Alexander's disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, balo concentric sclerosis, Canavan disease, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic idiopathic peripheral neuropathy, frontotemporal dementia, Huntington's disease, Krabbe disease, monomelic amyotrophy, multiple sclerosis (MS), neurodegeneration, neuromyelitis optica, neuropathic pain, neurosarcoidosis, Parkinson's disease, Pelizaeus-Merzbacher disease, primary lateral sclerosis, progressive supranuclear palsy, radicular pain, radiculopathic pain, Schilder's disease, sciatic pain, sciatica, subacute necrotizing myelopathy, transverse myelitis, or Zellweger syndrome, congenital or organic cognitive impairment, learning disabilities, autism spectrum disorder; or
the subject in need thereof desires cognitive enhancement, intelligence enhancement, creativity enhancement, memory improvement, learning enhancement, spiritual enhancement, “mind expansion,” IQ improvement, EQ improvement, balance enhancement, athleticism, motor skill enhancement, special navigation, clairvoyance, psychic enhancement, or general improvement of mental health.

### Claim 11

A method for administering psilocybin or psilocin to a subject in need thereof, the method comprising administering to the subject:
a first pharmaceutical dosage form comprising 10 mg to 30 mg of psilocybin, psilocin, pharmaceutically acceptable salts thereof, or a combination thereof; and
a second pharmaceutical dosage form comprising 0.01 mg to 10 mg of psilocybin, psilocin, pharmaceutically acceptable salts thereof, or a combination thereof, 1 to 6 times per day at regular intervals until the subject in need thereof does not require administration.

### Claim 12 (depends on 11)

The method of claim 11, wherein the first pharmaceutical dosage form comprises 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, or 30 mg of psilocybin, psilocin, or pharmaceutically acceptable salts thereof; and
the second pharmaceutical dosage form comprises 0.01 mg, 0.02 mg, 0.03 mg, 0.04 mg, 0.05 mg, 0.06 mg, 0.07 mg, 0.08 mg, 0.09 mg, 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5, mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg of psilocybin, psilocin, or pharmaceutically acceptable salts thereof.

### Claim 13

(canceled)

### Claim 14 (depends on 11)

The method of claim 11, wherein the first or second pharmaceutical dosage form comprises psilocybin or psilocin containing mushrooms or extracts thereof in an amount to provide an equivalent dose of psilocybin or psilocin.

### Claim 15 (depends on 11)

The method of claim 11, wherein the first or second pharmaceutical dosage form further comprises: 10 μg to 200 mg of niacin; one or more pharmaceutically acceptable excipients; or a combination thereof.

### Claim at position 15

16-17. (canceled)

### Claim 18 (depends on 11)

The method of claim 11, wherein the second pharmaceutical dosage form is administered 1 month, 2 months, 3 months, 4, months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2, years, 3 years, 4, years, 5 years, or a decade.

### Claim 19

(canceled)

### Claim 20 (depends on 11)

The method of claim 11, wherein the subject in need thereof is experiencing mood disorders, depression, anxiety, major depressive disorder, treatment resistant depression, persistent depression, manic depression or bipolar disorder, depressive psychosis, perinatal depression, premenstrual dysphoric disorder, seasonal depression, situational depression, panic disorder, post-traumatic stress disorder, obsessive compulsive disorder, substance abuse disorders, attention deficit/hyperactivity disorder, sleep disorders, eating disorders, schizophrenia, personality disorders, neuronal injuries or physical neurodegeneration, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, frontotemporal dementia, Huntington's disease, adrenal leukodystrophy, Alexander's disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, balo concentric sclerosis, Canavan disease, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic idiopathic peripheral neuropathy, frontotemporal dementia, Huntington's disease, Krabbe disease, monomelic amyotrophy, multiple sclerosis (MS), neurodegeneration, neuromyelitis optica, neuropathic pain, neurosarcoidosis, Parkinson's disease, Pelizaeus-Merzbacher disease, primary lateral sclerosis, progressive supranuclear palsy, radicular pain, radiculopathic pain, Schilder's disease, sciatic pain, sciatica, subacute necrotizing myelopathy, transverse myelitis, or Zellweger syndrome, congenital or organic cognitive impairment, learning disabilities, autism spectrum disorder; or
the subject in need thereof desires cognitive enhancement, intelligence enhancement, creativity enhancement, memory improvement, learning enhancement, spiritual enhancement, “mind expansion,” IQ improvement, EQ improvement, balance enhancement, athleticism, motor skill enhancement, special navigation, clairvoyance, psychic enhancement, or general improvement of mental health.

### Claim 21

A method for administering psilocybin or psilocin to a subject in need thereof, the method comprising administering to the subject:
a first pharmaceutical dosage form comprising 10 mg to 30 mg of psilocybin, psilocin, pharmaceutically acceptable salts thereof, or a combination thereof; and
a second pharmaceutical dosage form comprising 0-01 mg to 10 mg of psilocybin, psilocin, pharmaceutically acceptable salts thereof, or a combination thereof, 1 to 6 times per day at regular intervals until the subject in need thereof does not require administration.

### Claim 22 (depends on 21)

The method of claim 21, wherein the first pharmaceutical dosage form comprises 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, or 30 mg of psilocybin, psilocin, or pharmaceutically acceptable salts thereof; and
the second pharmaceutical dosage form comprises 0.01 mg, 0.02 mg, 0.03 mg, 0.04 mg, 0.05 mg, 0.06 mg, 0.07 mg, 0.08 mg, 0.09 mg, 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5, mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg of psilocybin, psilocin, or pharmaceutically acceptable salts thereof.

### Claim 23

(canceled)

### Claim 24 (depends on 21)

The method of claim 21, wherein the first and second pharmaceutical dosage form comprises psilocybin or psilocin containing mushrooms or extracts thereof in an amount to provide an equivalent dose of psilocybin or psilocin.

### Claim 25 (depends on 21)

The method of claim 21, wherein the first and second pharmaceutical dosage form further comprises; 10 μg to 200 mg of niacin; one or more pharmaceutically acceptable excipients; or a combination thereof.

### Claim at position 24

26-27. (canceled)

### Claim 28 (depends on 21)

The method of claim 21, wherein the second pharmaceutical dosage form is administered 1 month, 2 months, 3 months, 4, months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 12 months, 1 year, 2, years, 3 years, 4, years, 5 years, or a decade.

### Claim 29

(canceled)

### Claim 30 (depends on 21)

The method of claim 21, wherein the subject in need thereof is experiencing mood disorders, depression, anxiety, major depressive disorder, treatment resistant depression, persistent depression, manic depression or bipolar disorder, depressive psychosis, perinatal depression, premenstrual dysphoric disorder, seasonal depression, situational depression, panic disorder, post-traumatic stress disorder, obsessive compulsive disorder, substance abuse disorders, attention deficit/hyperactivity disorder, sleep disorders, eating disorders, schizophrenia, personality disorders, neuronal injuries or physical neurodegeneration, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, frontotemporal dementia, Huntington's disease, adrenal leukodystrophy, Alexander's disease, Alper's disease, Alzheimer's disease, amyotrophic lateral sclerosis, balo concentric sclerosis, Canavan disease, Charcot-Marie-Tooth disease, childhood ataxia with central nervous system hypomyelination, chronic idiopathic peripheral neuropathy, frontotemporal dementia, Huntington's disease, Krabbe disease, monomelic amyotrophy, multiple sclerosis (MS), neurodegeneration, neuromyelitis optica, neuropathic pain, neurosarcoidosis, Parkinson's disease, Pelizaeus-Merzbacher disease, primary lateral sclerosis, progressive supranuclear palsy, radicular pain, radiculopathic pain, Schilder's disease, sciatic pain, sciatica, subacute necrotizing myelopathy, transverse myelitis, or Zellweger syndrome, congenital or organic cognitive impairment, learning disabilities, autism spectrum disorder; or
the subject in need thereof desires cognitive enhancement, intelligence enhancement, creativity enhancement, memory improvement, learning enhancement, spiritual enhancement, “mind expansion,” IQ improvement, EQ improvement, balance enhancement, athleticism, motor skill enhancement, special navigation, clairvoyance, psychic enhancement, or general improvement of mental health.
